Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Cataract, Cellulitis, Dry eye
Clinical narrative: dry eyes; cellulitis; both eyes cataract; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 22K-163-4433870-00 (private).  A 65-year-old female patient received BNT162b2 (BNT162B2), on 23Feb2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 65 years intramuscular for covid-19 immunisation. The patient's relevant medical history included: "Non-Tobacco User" (unspecified if ongoing), notes: Non-Tobacco User; "Abstains from Alcohol" (unspecified if ongoing), notes: Abstains from Alcohol; "Penicillin Allergy" (unspecified if ongoing), notes: Penicillin Allergy manifested by Rash; "Rash" (unspecified if ongoing), notes: Penicillin Allergy manifested by Rash. Concomitant medication(s) included: HUMIRA subcutaneous taken for rheumatoid arthritis, start date: Jan2021, stop date: 2022; NARDIL; METHOTREXATE; PRAMIPEXOLE; KLONOPIN; LITHIUM CARBONATE; METFORMIN; VALTREX; CEPHALEXIN [CEFALEXIN]; PENICILLIN [PENICILLIN NOS]. Vaccination history included: BNT162b2 (Daily Dose: , 1) First dose (1 in 1 Once), Route of Admin: 1) Intramuscular, Indication for use: COVID-19 Vaccination, Therapy Dates/Duration: , 1)08Mar2021 - 08Mar2021), administration date: 08Mar2021, when the patient was 64-year-old, for Covid-19 Immunization; BNT162b2 (Daily Dose: , 2) Second dose (1 in 1 Once), Route of Admin: 2) Intramuscular, Indication for use: COVID-19 Vaccination, Therapy Dates/Duration: , 2) 05Apr2021 - 05Apr2021), administration date: 05Apr2021, when the patient was 64-year-old, for Covid-19 Immunization; BNT162b2 (Daily Dose: , 3) First booster (1 in 1 Once), Route of Admin: 3) Intramuscular, Indication for use: COVID-19 Vaccination, Therapy Dates/Duration: , 3) 31Aug2021 - 31Aug2021), administration date: 31Aug2021, when the patient was 64-year-old, for Covid-19 Immunization.  The following information was reported: CATARACT (medically significant) with onset 2022, outcome "not recovered", described as "both eyes cataract"; CELLULITIS (medically significant) with onset Jul2022, outcome "recovered" (2022); DRY EYE (medically significant), outcome "unknown", described as "dry eyes". The event "cellulitis" required emergency room visit. Therapeutic measures were taken as a result of cataract, cellulitis. Clinical course: An elderly female with events of both eyes cataract and non-serious cut on right leg, dry eyes, got an infection after hit by truck, cellulitis, Staphyloccus infection and food and drug interaction due to Nardil with Humira 40mg/0.4ml (Adalimumab). The patient has other concomitant therapy of Penicillin. On unknown dates, the patient experienced dry eyes, got an infection after hit by truck and food and drug interaction due to Nardil. In May2021, the patient experienced Staphyloccus infection. On 07May2021, the patient experienced cut on right leg and got an infection after hit by truck. In 2022, the patient experienced both eyes cataract. In Jul2022, the patient experienced cellulitis. In 2022, the cellulitis resolved. On unknown dates, cut on right leg and Staphyloccus infection resolved. Nardil (Phenelzine Sulfate) was also considered suspect.  The patient had an accident on 07May2021 where she was hit by a truck. She noted her right leg started to get red on 16May2021 and had become bright red on 19May2021. She went to the emergency room on 20May2021. She was told early this year on 2022 to have a cataract surgery. Doctor had it sooner since it had gotten worse. She had it on two occasions, one eye each time. Right eye was on 13Apr2022 and left eye was on 27Apr2022.  She mentioned she was given four kinds of eye drops, an anti-inflammatory, and antibiotic. She was prescribed an antibiotic and she said after seven days it cleared up pretty quickly. On 06Jul2022 her doctor looked at her leg and it was pinkish. She was prescribed an antibiotic as precaution. On 22Jul2022, her leg went red again. She went to the emergency room on 26Jul2022 and was diagnosed with Cellulitis. She was prescribed another antibiotic. She mentioned she finished the antibiotic on 03Aug2022. She held off Humira for a week after she received her Covid booster on 31Aug2022. But she said she might had been on her off week with Humira at that time as well. She also mentioned she had food and drug interaction due to Nardil. She was taking unspecified supplements.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.  Primary reporter did not have the lot number information, because the packaging was discarded. The patient was treated with Doxycycline.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.